ANI Pharmaceuticals launches generic version of Cymbalta
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St on pace for higher open as oil pulls back ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts ANIP Hot Sheet
Join SI Premium – FREE
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced the launch of Duloxetine Delayed-Release Capsules in 20, 30, and 60 mg doses, a generic version of the branded drug Cymbalta.
U.S. annual sales for Duloxetine Delayed-Release Capsules totaled approximately $247 million, based on August 2026 moving annual total data from IQVIA.
Nikhil Lalwani, President and Chief Executive Officer of ANI Pharmaceuticals, said the launch provides "another alternative of a widely used therapy in a limited player market to assure stable supply."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- City Holding (CHCO) PT Raised to $147 at Keefe, Bruyette & Woods
- StoneX Reiterates Buy Rating on Intel (INTC) Ahead of Earnings
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Maynard Um, Mark Zuckerberg, Irina Koffler, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
